Thursday, April 20, 2017 7:16:20 AM
CNW Group CNW GroupApril 20, 2017
TSXV: ACB
VANCOUVER , April 20, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (ACB.V) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line of ingestible cannabis oils called Aurora Drops.
The Company's newest offerings include three distinct product types all priced equally at a standard flat rate of $115 per bottle, or $80 per bottle for clients approved for Aurora's compassionate pricing program:
THC Drops (Sativa) – a high potency THC oil extracted from Cannabis Sativa flowers
THC Drops (Indica) – a high potency THC oil extracted from Cannabis Indica flowers
CBD Drops – a high potency oil extracted from Aurora's flagship CBD strain Temple (Cannatonic)
The Company's ingestible cannabis oils come in 30 ml glass bottles with a child resistant certified cap and dropper to allow for the easy and accurate dosing of small amounts of the high potency fluids, and are produced using CGMP compliant supercritical CO2 extraction technology, as well as using an MCT carrier oil sourced from coconut oil.
As with all of Aurora's cannabis products, the test results from the independent third-party lab for each batch of ingestible oil are publicly available. Test results can be accessed online at auroramj.com/strains, or through the Aurora Mobile app, a feature rich mobile experience for iOs and Android that displays inventory tracking and restocking events, and sends push notifications for new product releases.
"The launch of our first ingestible oil products represents a major milestone, which promises to add significantly to Aurora's top and bottom line results," said Neil Belot , Chief Global Business Development Officer. "We have produced a sizeable inventory of Aurora Drops for our domestic medical client base, and will be continuing to ramp up production in order to address the strong demand we anticipate for high-quality, high-margin derivative products, manufactured under the rigorous Aurora Standards regarding processes, testing, and transparency."
The Company recently signed a Memorandum of Understanding with Radient Technologies Inc. ("RTI") with regards to the joint development and commercialization in Canada of superior and standardized cannabinoid extracts produced using RTI's high-throughput, terpene-preserving, proprietary extraction technology.
"The strategic partnership with RTI has the potential to be a game changer in this high-margin, high-growth segment of the cannabis market, "said Terry Booth , CEO. "If the technology works as we anticipate, Aurora will be able to produce high volumes of terpene-rich cannabis derivatives at lower costs and much shorter harvest-to-market times than any company using current industry benchmark technologies. This would give us an even stronger competitive advantage in what may well become the dominant market segment. The launch of sales is the first step in establishing our brand in the derivatives market, and we are very pleased that we are able to expand our offering to a customer base looking for alternative methods to consume cannabis."
The companies' technical feasibility and commercial opportunities study currently underway is proceeding well, and is expected to be completed soon.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed
Recent ACB News
- Aurora Improves Offerings in Australia with New Range of Premium Dried Flower Products • PR Newswire (US) • 04/30/2024 11:15:00 AM
- Aurora Improves Offerings in Australia with New Range of Premium Dried Flower Products • PR Newswire (Canada) • 04/30/2024 11:15:00 AM
- Marijuana Stocks Up After Banking Reform Progress • IH Market News • 04/09/2024 10:05:42 AM
- Aurora Cannabis Commends Germany's Landmark Legalization Achievement • PR Newswire (US) • 04/01/2024 11:00:00 AM
- Aurora Cannabis Commends Germany's Landmark Legalization Achievement • PR Newswire (Canada) • 04/01/2024 11:00:00 AM
- Aurora Cannabis Achieves Australia's TGA GMP Certification, Setting Global Standard for Quality and Compliance • PR Newswire (Canada) • 03/20/2024 11:15:00 AM
- Aurora Cannabis Achieves Australia's TGA GMP Certification, Setting Global Standard for Quality and Compliance • PR Newswire (US) • 03/20/2024 11:15:00 AM
- Aurora Introduces Medical Cannabis Pastilles for Patient Relief in Australia • PR Newswire (Canada) • 03/04/2024 02:42:00 PM
- Aurora Introduces Medical Cannabis Pastilles for Patient Relief in Australia • PR Newswire (US) • 03/04/2024 02:42:00 PM
- Aurora Completes Final Repayment of Convertible Senior Notes Representing ~$465 Million in Total Repayments Since 2021; Cannabis Operations Are Now Debt Free[1] • PR Newswire (Canada) • 02/29/2024 10:00:00 PM
- Aurora Completes Final Repayment of Convertible Senior Notes Representing ~$465 Million in Total Repayments Since 2021; Cannabis Operations Are Now Debt Free[1] • PR Newswire (US) • 02/29/2024 10:00:00 PM
- Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis • PR Newswire (US) • 02/28/2024 12:13:00 PM
- Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis • PR Newswire (Canada) • 02/28/2024 12:11:00 PM
- Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis • PR Newswire (US) • 02/28/2024 12:11:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 12:36:30 PM
- Aurora Cannabis Announces CFO Transition and Completion of Previously Announced Share Consolidation • PR Newswire (Canada) • 02/20/2024 12:00:00 PM
- Aurora Cannabis Announces CFO Transition and Completion of Previously Announced Share Consolidation • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/16/2024 02:49:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 12:23:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 12:10:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 12:07:18 PM
- Aurora Cannabis Announces Fiscal 2024 Third Quarter Results; Generates Record Adjusted EBITDA of $4.3 Million • PR Newswire (Canada) • 02/08/2024 12:00:00 PM
- Aurora Cannabis Announces Fiscal 2024 Third Quarter Results; Generates Record Adjusted EBITDA of $4.3 Million • PR Newswire (US) • 02/08/2024 12:00:00 PM
- Aurora Cannabis Acquires MedReleaf Australia • PR Newswire (US) • 02/08/2024 11:45:00 AM
- Aurora Cannabis Acquires MedReleaf Australia • PR Newswire (Canada) • 02/08/2024 11:45:00 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM